Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acsé Vemurafenib
2024-514904-14-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in non-small cell lung cancer (NSCLC), ovarian cancer, cholangiocarcinoma (CCA) and 9 more, sponsored by Unicancer. Primary endpoint: Confirmed objective response/remission rate. Planned start Jul 2024; status: authorised.
02
Drugs
vemurafenib
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancercholangiocarcinoma (CCA)thyroid cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2024-514904-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514904-14-00.